International Stem Cell Corporation / "Executive Compensation" | Tables in SEC filings

ISCO International Stem Cell Corporation

Definitive proxy

As required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act, and Item 402(v) of Regulation S-K, we are providing the following information about the relationship between executive compensation actually paid to our named executive officers and certain financial performance of the Company.


Year		Summary Compensation Table Total for PEO(1)			Compensation Actually Paid to PEO(2)			Average Summary Compensation Table Total for Non-PEO NEOs(3)			Average Compensation Actually Paid to Non-PEO NEOs(4)			Value of Initial Fixed $100 Investment Based On Total Shareholder Return(5)			Net Income (Loss)(6)
2023	$		112,865	$		81,567	$		377,237	$		265,340	$		33.33	$		(131,000)
2022	$		396,143	$		228,263	$		249,972	$		81,555	$		38.30	$		(331,000)

Table search / International Stem Cell Corporation / "Executive Compensation"

1 result

Top filers

Top filing types

Recent filing years